Tonix Pharma Reveals Mpox Clade IIb Is 100,000x Less Virulent
Tonix Pharmaceuticals study in Journal of Virology shows mpox clade IIb is up to 100,000 times less virulent than clade IIa, supporting TNX-801 vaccine development.
This research matters because it provides critical insights into the virulence of the current mpox strain, enabling more targeted vaccine and treatment development. The new mouse models will help scientists evaluate emerging variants, potentially leading to better preparedness against future outbreaks and safeguarding public health.
